NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/organon-co-lawsuit-submission-for ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in 3D Systems Corporation ("3D Systems Corporation" or the "Company") (NYSE: DDD) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of 3D Systems Corporation investors who were adversely affected by alleged securities fraud between August 13, 2024 and May 12, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra ...

NEW YORK, July 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Red Cat Holdings, Inc. ("Red Cat Holdings, Inc." or the "Company") (NASDAQ: RCAT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Red Cat Holdings, Inc. investors who were adversely affected by alleged securities fraud between March 18, 2022 and January 15, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra- ...

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-offs [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward due to "recent launch dynamics" and high patient drop-off rates [5]. - Following the announcement, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charg ...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Compass you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/compass-diversified-holdings. Investors ...

BENSALEM, Pa., July 3, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Off ...

BENSALEM, Pa., July 2, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ROCKET PHARMACEUTICALS, INC. (RCKT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 11, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact ...

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].